产品名称

英文名称：Bavisant

同义词

BAVISANT、929622-08-2、JNJ-31001074、UNII-9827P7LFVH、Bavisant [USANINN]、9827P7LFVH、929622-08-2(free base)、(4-Cyclopropylpiperazin-1-yl)(4-(morpholin-4-ylmethyl)phenyl)methanone、(4-cyclopropylpiperazin-1-yl)-[4-(morpholin-4-ylmethyl)phenyl]methanone、Methanon

产品性质

CAS编号：929622-08-2

分子式：C19H27N3O2

分子量：329.44

PubChem编号：16061509

英文别名：BAVISANT|929622-08-2|JNJ-31001074|UNII-9827P7LFVH|Bavisant [USANINN]|9827P7LFVH|929622-08-2(free base)|(4-Cyclopropylpiperazin-1-yl)(4-(morpholin-4-ylmethyl)phenyl)methanone|(4-cyclopropylpiperazin-1-yl)-[4-(morpholin-4-ylmethyl)phenyl]methanone|Methanon

英文名称：Bavisant

生化机理：DescriptionIC50 Value N/ABavisant (JNJ-31001074) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD. Bavisant completed a phase II ADHD trial, but no results have been reported [1].in vitro N/Ain vivo Mean change from baseline in the total ADHD-RS-IV score at day 42 (primary efficacy endpoint) was -8.8 in the placebo group versus -9.3, -11.2 and -12.2 in the bavisant 1?mg/day, 3?mg/day and 10?mg/day groups, respectively; the change in the 10?mg/day group was not statistically superior to placebo (p=0.161), and hence statistical comparisons of the 1?mg/day and 3?mg/day groups with placebo based on a step-down closed testing procedure were not performed [2].Clinical trial A Study to Characterize the Pharmacokinetics and Effect of Food on JNJ-31001074 in Healthy Volunteers. Phase 2

储存温度：-20°C储存

运输条件：超低温冰袋运输

ALogP：1.2

IUPAC Name：(4-cyclopropylpiperazin-1-yl)-[4-(morpholin-4-ylmethyl)phenyl]methanone

INCHI：InChI=1S/C19H27N3O2/c23-19(22-9-7-21(8-10-22)18-5-6-18)17-3-1-16(2-4-17)15-20-11-13-24-14-12-20/h1-4,18H,5-15H2

InChi Key：BGBVSGSIXIIREO-UHFFFAOYSA-N

Canonical SMILES：C1CC1N2CCN(CC2)C(=O)C3=CC=C(C=C3)CN4CCOCC4

Isomeric SMILES：C1CC1N2CCN(CC2)C(=O)C3=CC=C(C=C3)CN4CCOCC4

PubChem CID：16061509

溶解性：25°C DMSO

产品包装